✦ Spread pricing by PBMs is inflating health care spending in Massachusetts. So states the Massachusetts Health Policy Commission, which issued a recent analysis finding PBM prices for generic drugs in MassHealth, the state’s Medicaid managed care program, exceeded acquisition prices for 95% of the drugs analyzed in the fourth quarter of 2018. “Furthermore,” the report says, “for those drugs where MCOs paid a higher price than [fee-for-service], the difference was often substantial, leading to higher average drug prices overall. MCO prices exceeded FFS prices by an average $15.97 per unique drug, despite being below FFS prices for more than half (58%) of unique drugs.” View the report at https://bit.ly/2wPoi6L.
To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.